CoChat
Sign Up
Cited by 68Liver physiology and pathologyHepatitis C virus researchLiver Disease Diagnosis and Treatment

Antifibrotic Agents for Liver Disease

Open access
Albanis, E., Friedman, S.L.·2006·American Journal of Transplantation
DOI 10.1111/j.1600-6143.2005.01143.x
Open this paper in CoChat — free accountOpen PDF

Abstract

Complications from chronic hepatitis C (HCV) and recurrent HCV post-transplant are responsible for significant morbidity and mortality in the United States and Europe. Current antiviral therapies are at best, effective in up to 50% of patients in the pre-transplant setting, and in the post-transplant setting are associated with more limited efficacy and increased toxicity. With this reduced efficacy of antiviral strategies in the post-transplant setting, new approaches are urgently needed. Substantial progress has been made in understanding the pathogenesis of hepatic fibrosis over the last 20 years, which has yielded potential new therapeutic targets. The prospect of antifibrotic therapies is nearing reality in order to reduce progression to cirrhosis, thereby reducing morbidity, mortality and the need for re-transplantation. Current and evolving approaches primarily target the activated hepatic stellate cells, which are the main source of extracellular matrix, along with related fibrogenic cell types. Key issues yet to be clarified include the optimal duration of antifibrotic therapies, endpoints of clinical trials, indications in clinical practice and whether combination therapies might yield synergistic activity.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1600-6143.2005.01143.x

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 65

  1. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003; 9: 331-338.
  2. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-562.
  3. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
  4. Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 815-820.
  5. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell sur- vival. Science 1998; 281: 1322-1326.
  6. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M et al. HCV-related fibrosis progression following liver transplanta- tion: increase in recent years. J Hepatol 2000; 32: 673-684.
  7. Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl 2003; 9: S28- S34.
  8. Neumann UP, Berg T, Bahra M, Puhl G, Guckelberger O, Langrehr JM et al. Long-term outcome of liver transplants for chronic hep- atitis C: a 10-year follow-up. Transplantation 2004; 77: 226-231.
  9. Berenguer M, Prieto M, Rayon JM, Mora J, Pastor M, Ortiz V et al. Natural history of clinically compensated hepatitis C virus- related graft cirrhosis after liver transplantation. Hepatology 2000; 32: 852-858.
  10. Berenguer M, Prieto M, San Juan F, Rayon JM, Martinez F, Carrasco D et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36: 202-210.
  11. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after ortho- topic liver transplantation. Gastroenterology 2002; 122: 889-896.
  12. Albanis E, Friedman SL. Hepatic fibrosis. Pathogenesis and prin- ciples of therapy. Clin Liver Dis 2001; 5: 315-334, v-vi.
  13. Kweon YO, Goodman ZD, Dienstag JL, Schiff ER, Brown NA, Burkhardt E et al. Decreasing fibrogenesis: an immunohistochem- ical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol 2001; 35: 749-755.
  14. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Good- man Z et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-1313.
  15. Issa R, Zhou X, Constandinou CM, Fallowfield J, Millward-Sadler H, Gaca MD et al. Spontaneous recovery from micronodular cir- rhosis: Evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology 2004; 126: 1795-1808.
  16. Pinzani M, Milani S, Grappone C, Weber FJ, Gentilini P, Abboud HE et al. Expression of platelet-derived growth factor in a model of acute liver injury. Hepatology 1994; 19: 701-707.
  17. Friedman SL. Molecular regulation of hepatic fibrosis, an inte- grated cellular response to tissue injury. J Biol Chem 2000; 275: 2247-2250.
  18. Pinzani M, Marra F. Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis 2001; 21: 397-416.
  19. Olaso E, Friedman SL. Molecular regulation of hepatic fibrogene- sis. J Hepatol 1998; 29: 836-847.
  20. Bachem MG, Riess U, Melchior R, Sell KM, Gressner AM. Trans- forming growth factors (TGF alpha and TGF beta 1) stimulate chondroitin sulfate and hyaluronate synthesis in cultured rat liver fat storing cells. Febs Lett 1989; 257: 134-137.
  21. Dooley S, Delvoux B, Lahme B, Mangasser-Stephan K, Gressner AM. Modulation of transforming growth factor beta response and signaling during transdifferentiation of rat hepatic stellate cells to myofibroblasts. Hepatology 2000; 31: 1094-1106.
  22. Rockey DC. Hepatic blood flow regulation by stellate cells in nor- mal and injured liver. Seminars in Liver Disease 2001; 21: 337- 350.
  23. Rockey D, Chung J. Inducible nitric oxide synthase in rat hepatic lipocytes and the effect of nitric oxide on lipocyte contractility. J Clin Invest 1995; 95: 1199-1206.
  24. Benyon D, Arthur MJP. Extracellular matrix degradation and the role of stellate cells. Semin Liver Dis 2001; 21: 373-384.
  25. Iredale JP. Stellate cell behavior during resolution of liver injury. Semin Liver Dis 2001; 21: 427-436.
  26. Iredale JP, Benyon RC, Pickering J, McCullen M, Northrop M, Pawley S et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998; 102: 538-549.
  27. Gentilini A, Marra F, Gentilini P, Pinzani M. Phosphatidylinositol- 3 kinase and extracellular signal-regulated kinase mediate the chemotactic and mitogenic effects of insulin-like growth factor-I in human hepatic stellate cells. J Hepatol 2000; 32: 227-234.
  28. Tangkijvanich P, Tam SP, Yee HF, Jr. Wound-induced migration of rat hepatic stellate cells is modulated by endothelin-1 through rho-kinase-mediated alterations in the acto-myosin cytoskeleton. Hepatology 2001; 33: 74-80.
  29. Friedman SL, Arthur MJ. Reversing hepatic fibrosis. Sci Med 2002; 8: 194-205.
  30. Gilmore IT, Burroughs A, Murray-Lyon IM, Williams R, Jenkins D, Hopkins A et al. Indications, methods, and outcomes of percuta- neous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut 1995; 36: 437-441.
  31. McGill DB, Rakela J, Zinsmeister AR, Ott BJ. A 21-year expe- rience with major hemorrhage after percutaneous liver biopsy. Gastroenterology 1990; 99: 1396-1400.
  32. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epi- demiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000; 32: 477-481.
  33. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975- 982.
  34. Hadziyannis SJ, Sette H, Jr, Morgan TR, Balan V, Diago M, Marcellin P et al. Peginterferon-alpha2a and ribavirin combina- tion therapy in chronic hepatitis C: a randomized study of treat- ment duration and ribavirin dose. Ann Intern Med 2004; 140: 346- 355.
  35. Guido M, Rugge M. Liver biopsy sampling in chronic viral hepati- tis. Semin Liver Dis 2004; 24: 89-97.
  36. Soloway RD, Baggenstoss AH, Schoenfield LJ, Summerskill WH. Observer error and sampling variability tested in evaluation of hepatitis and cirrhosis by liver biopsy. Am J Dig Dis 1971; 16: 1082-1086.
  37. Abdi W, Millan JC, Mezey E. Sampling variability on percutaneous liver biopsy. Arch Intern Med 1979; 139: 667-669.
  38. Maharaj B, Maharaj RJ, Leary WP, Cooppan RM, Naran AD, Pirie D et al. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986; 1: 523-525.
  39. Baunsgaard P, Sanchez GC, Lundborg CJ. The variation of patho- logical changes in the liver evaluated by double biopsies. Acta Pathol Microbiol Scand [A] 1979; 87: 51-57.
  40. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gas- troenterol 2002; 97: 2614-2618.
  41. Rockey DC, Chung JJ. Interferon gamma inhibits lipocyte acti- vation and extracellular matrix mRNA expression during experi- mental liver injury: implications for treatment of hepatic fibrosis. J Investig Med 1994; 42: 660-670.
  42. Ueki T, Kaneda Y, Tsutsui H et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 1999; 5: 226-230.
  43. Galli A, Crabb DW, Ceni E, Salzano R, Mello T, Svegliati-Baroni G et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroen- terology 2002; 122: 1924-1940.
  44. Kon K, Ikejima K, Hirose M, Yoshikawa M, Enomoto N, Kitamura T et al. Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride. Biochem Biophys Res Commun 2002; 291: 55-61.
  45. Marra F, Efsen E, Romanelli RG, Caligiuri A, Pastacaldi S, Batig- nani G et al. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 2000; 119: 466-478.
  46. Houglum K, Venkataramani A, Lyche K, Chojkier M. A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell acti- vation in chronic hepatitis C. Gastroenterology 1997; 113: 1069- 1073.
  47. Shimizu I, Ma YR, Mizobuchi Y, Liu F, Miura T, Nakai Y et al. Effects of Sho-saiko-to, a Japanese herbal medicine, on hepatic fibrosis in rats [see comments]. Hepatology 1999; 29: 149-160.
  48. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM et al. Activity of a specific inhibitor of the BCR-ABL tyrosine ki- nase in the blast crisis of chronic myeloid leukemia and acute lym- phoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-1042.
  49. Okuno M, Moriwaki H, Muto Y, Kojima S. Protease inhibitors sup- press TGF-beta generation by hepatic stellate cells. J Hepatol 1998; 29: 1031-1032.
  50. Nakamura T, Sakata R, Ueno T, Sata M, Ueno H. Inhibition of trans- forming growth factor beta prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine- treated rats. Hepatology 2000; 32: 247-255.
  51. George J, Roulot D, Koteliansky VE, Bissell DM. In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. Proc Natl Acad Sci U S A 1999; 96: 12719-12724.
  52. Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Suzuki Y, Mez- zano S et al. Role of the renin-angiotensin system in vascular dis- eases: expanding the field. Hypertension 2001; 38: 1382-1387.
  53. Brown NJ, Vaughan DE, Fogo AB. The renin-angiotensin- aldosterone system and fibrinolysis in progressive renal disease. Semin Nephrol 2002; 22: 399-406.
  54. Gaedeke J, Peters H, Noble NA, Border WA. Angiotensin II, TGF- beta and renal fibrosis. Contrib Nephrol 2001; 135: 153-160.
  55. Ruiz-Ortega M, Lorenzo O, Suzuki Y, Ruperez M, Egido J. Proin- flammatory actions of angiotensins. Curr Opin Nephrol Hypertens 2001; 10: 321-329.
  56. Arroyo V, Bosch J, Mauri M, Viver J, Mas A, Rivera F et al. Renin, aldosterone and renal haemodynamics in cirrhosis with ascites. Eur J Clin Invest 1979; 9: 69-73.
  57. Bataller R, Gines P, Nicolas J et al. Angiotensin II induces contrac- tion and proliferation of human hepatic stellate cells. Gastroen- terology 2000; 118: 1149-1156.
  58. Bataller R, Gabele E, Parsons CJ, Morris T, Yang L, Schoonhoven R et al. Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats. Hepatology 2005; 41: 1046- 1055.
  59. Yoshiji H, Yoshii J, Ikenaka Y, Noguchi R, Tsujinoue H, Nakatani T et al. Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats. J Hepatol 2002; 37: 22-30.
  60. Jonsson JR, Clouston AD, Ando Y, Kelemen LI, Horn MJ, Adamson MD et al. Angiotensin-converting enzyme inhibition at- tenuates the progression of rat hepatic fibrosis. Gastroenterology 2001; 121: 148-155.
  61. Croquet V, Moal F, Veal N et al. Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hyper- tension. J Hepatol 2002; 37: 773-780.
  62. Boffa JJ, Lu Y, Placier S, Stefanski A, Dussaule JC, Chatzianto- niou C et al. Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metallopro- teinases. J Am Soc Nephrol 2003; 14: 1132-1144.
  63. Yu Q, Shao R, Qian HS, George SE, Rockey DC. Gene transfer of the neuronal NO synthase isoform to cirrhotic rat liver ameliorates portal hypertension. J Clin Invest 2000; 105: 741-748.
  64. Salgado S, Garcia J, Vera J, Siller F, Bueno M, Miranda A et al. Liver cirrhosis is reverted by urokinase-type plasminogen activa- tor gene therapy. Mol Ther 2000; 2: 545-551.
  65. Wright M, Issa R, Smart D et al. Gliotoxin stimulates the apop- tosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. Gastroenterology 2001; 121: 685-698.

Cited by

Sorted by citations

Authors
Albanis, E., & Friedman, S. L.
Affiliations
Mount Sinai Hospital (US)
Corresponding author
Albanis, E.
ORCID
Friedman, S.L.
Venue
American Journal of Transplantation
Publisher
Elsevier BV
Published
2006-01
Volume
6
Issue
1
Pages
12-19
ISSN
1600-6135 (ISSN-L)
DOI
10.1111/j.1600-6143.2005.01143.x
OpenAlex
W1972595485
Cited by
68
References
0
Citations by year
2025: 1 · 2024: 1 · 2023: 1 · 2022: 3 · 2021: 3 · 2020: 1 · 2019: 1 · 2018: 4 · 2017: 2 · 2016: 3 · 2015: 3 · 2014: 3 · 2013: 3
FWCI
0.99
Type
journal article
Language
en
Open access
Licence
Locations
  • American Journal of Transplantation (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
American Association for the Study of Liver Diseases
Topics
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Health Sciences › Medicine › Hepatology › Hepatitis C virus research
  • Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
Keywords
antifibrotic agents, liver fibrosis, chronic hepatitis C, post-transplant hepatitis C, hepatic stellate cells, extracellular matrix, liver cirrhosis, antiviral therapy, liver transplantation, combination therapy, fibrosis pathogenesis
MeSH terms
Fibrosis, Humans, Liver Cirrhosis, Drug Design, Liver Transplantation, Hepatitis C, Chronic, Hepatocytes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review